The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
According to reports, Verano Holdings Corp. has submitted formal applications to register its state-licensed medical cannabis operations with the U.S. Drug Enforcement Administration (DEA). This strategic move follows the federal rescheduling of medical marijuana to Schedule III under the Controlled Substances Act. The company is seeking to utilize the expedited regulatory pathways created by this significant shift in federal policy.
Sign in to access this content
Sign InThis action marks a pivotal moment for the U.S. cannabis sector, as experts suggest DEA registration could lead to the elimination of tax burdens under Section 280E, which currently prevents cannabis firms from deducting ordinary business expenses. In comparison to peers, Curaleaf Holdings (CURLF) reported a 2% revenue increase in its latest quarter per its earnings release, while Verano aims to strengthen its institutional standing. Per market data, this move toward federal legitimacy is expected to improve access for institutional investors who previously avoided cannabis-linked assets.
VRNO shares will be closely watched as investors monitor the DEA's response to these applications as a primary catalyst. According to the economic calendar, U.S. Initial Jobless Claims data due on May 7, 2026, may influence broader market sentiment toward growth stocks. Investors should also monitor upcoming central bank commentary, including the speech by Fed's Goolsbee on May 6, 2026, to assess general liquidity conditions that could impact small-cap equity performance.